Compare Invesco DB Oil Fund (DBO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs Merck & Co., Inc. — how do they compare? Invesco DB Oil Fund trades at $24.13 (market cap $255.13M), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 1376.9× Invesco DB Oil Fund's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Invesco DB Oil Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and Merck & Co., Inc. for 98 Days on average.
| DBO | MRK | |
|---|---|---|
Market Cap | $255.13M | $351.28B |
Volume | 562,167 | 7,969,665 |
Sector | Commodities - Energy | Health |
52-Week High | $26.35 | $156.43 |
52-Week Low | $11.98 | $82.49 |
Typical Hold Time | 31 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $24.13, up 2.51% today amid mixed oil market signals. Technical indicators show a neutral overall signal with bearish moving averages, while oscillators remain neutral. Recent news highlights Middle East supply disruptions and OPEC+ production decisions creating volatility in energy markets. The stock faces resistance at $24 and support at $23 levels.
The outlook remains uncertain with geopolitical tensions supporting oil prices but strategic reserve releases creating downward pressure. Key risks include supply chain disruptions and regulatory challenges, while institutional sentiment appears cautious given the mixed technical signals and market volatility.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
